PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19
By Nicole Longo | May 6, 2020
The COVID-19 pandemic has caused a number of disruptions in our health care system, one of which is the ability for seniors to access their infused or injected Part B medicines normally...
Read More
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
By Tom Wilbur | May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...
Read More
The continued imperative to protect U.S. innovation worldwide
By Chris Moore | April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Guest Post: Preserving clinical research sites during the coronavirus pandemic
By Guest Contributor | April 29, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Observing National Minority Health Month in the age of COVID-19
By Courtney Christian | April 24, 2020
Every April, National Minority Health Month is observed. The month is dedicated to continuing to raise awareness about health disparities affecting racial and ethnic minority groups. Each year,...
Read More
New report shows nearly 260 vaccines in development, including dozens for COVID-19
By Andrew Powaleny | April 23, 2020
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most...
Read More
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
By Katie Koziara | April 20, 2020
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...
Read More
Retail medicine spending to remain stable share of overall health care spending through next decade
By Holly Campbell | April 16, 2020
National Health Expenditure (NHE) data projections recently released by the Centers for Medicare & Medicaid Services (CMS) indicate retail medicine spending grew 3.2% in 2019 and will continue to...
Read More
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
By Stephen J. Ubl | April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have created programs empowering employees with medical or laboratory expertise to...
Read More
Guest post: Securing the health care supply chain during COVID-19
By Guest Contributor | April 14, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
